The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2021 | The current treatment landscape for T-cell lymphoma
Deepa Jagadeesh, MD, PhD, Case Comprehensive Cancer Center, Cleveland, OH, gives an overview of the current treatment landscape for patients with T-cell lymphomas. For patients who are CD30-positive, Dr Jagadeesh highlights the use of brentuximab vedotin plus CHOP, which was approved based on the results of the ECHELON-2 trial (NCT01777152). For CD30-negative patients, Dr Jagadeesh reports the use of CHOP-based regimens, and in patients over 60, comments on the addition of etoposide to the treatment regimen. In the relapsed/refractory setting, single agent approaches are typically used. Finally, Dr Jagadeesh comments on the role of transplantation for patients with T-cell lymphomas. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Deepa Jagadeesh, MD, PhD, has received research funding from ADC Therapeutics, AstraZeneca, Debiopharm Group, MEI Pharma, Regeneron, Rhizen Pharma, Seagen, Trillium Therapeutics and LOXO Pharma.
